Venous thromboembolic diseases: diagnosis, management and thrombophilia testing
KEYWORDS: people, treatment, anticoagulation, dvt, committee, anticoagulation treatment, evidence, vte, recommendations, risk, cancer, agreed, clinical, use, d-dimer

cancer, and the person's bleeding risk. [2020] 1.3.17 Consider a direct-acting oral anticoagulant (DOAC) for people with active cancer and confirmed proximal DVT or PE. [2020] 1.3.18 If a DOAC is unsuitable consider LMWH alone or LMWH concurrently with a VKA for at least 5 days, or until the INR is at least 2.0 in 2 consecutive readings, followed by a VKA on its own. [2020] 1.3.19 For people with confirmed DVT or PE and cancer that is in remission, follow the recommendations in the section on anticoagulation treatment for confirmed DVT or PE. [2020] Anticoagulation treatment for DVT or PE with triple positive antiphospholipid syndrome 1.3.20 Offer people with confirmed proximal DVT or PE and an established diagnosis of triple positive antiphospholipid syndrome LMWH concurrently with a VKA for at least 5 days, or until the INR is at least 2.0 in 2 consecutive readings, followed by a VKA on its own. [2020] Treatment failure 1.3.21 If anticoagulation treatment fails: • check adherence to anticoagulation treatment • address other sources of hypercoagulability • increase the dose of anticoagulant or change to an anticoagulant with a different mode of action. [2020] NICE technology appraisal guidance on anticoagulation treatment for confirmed
